Cited by 966Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Poole, Kenneth E. S., Van Bezooijen, Rutger L., Loveridge, Nigel, Hamersma, Herman, Papapoulos, Socrates E., Löwik, Clemens W., Reeve, Jonathan·2005·The FASEB Journal

DOI 10.1096/fj.05-4221fje

Open this paper in CoChat — free account

Abstract

Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte‐derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.

Integrity signals

Registry

Crossref · 10.1096/fj.05-4221fje

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling‐Hampton, K., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,114
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Self-citation
Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L. J. A., de Wilt, E., Karperien, M., Hamersma, H. A., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 893
Self-citation
Loss of Osteocyte Integrity in Association with Microdamage and Bone Remodeling After Fatigue In Vivo
Verborgt, O., Gibson, G. J., & Schaffler, M. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.60 · Cited by 731
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells
Dobnig, H., & Turner, R. T. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628403 · Cited by 614
Periosteum: biology, regulation, and response to osteoporosis therapies
Allen, M. R., Hock, J. M., & Burr, D. B. (2004) · Bone · doi:10.1016/j.bone.2004.07.014 · Cited by 449
The Death of Osteocytes via Apoptosis Accompanies Estrogen Withdrawal in Human Bone
Tomkinson, A., REEVE, J., Shaw, R. W., & Noble, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4200 · Cited by 417
Self-citation

Show all 34 references

Research works printed but not linked: 2

Warmington K., 2004, Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood (Abstract), J. Back Musculoskeletal. Rehabil., 19, S56
10.1210/jc.82.9.3128 · DOI

Sorted by citations

Items 101–200 of 966

Interplay between Inflammation and Pathological Bone Resorption: Insights into Recent Mechanisms and Pathways in Related Diseases for Future Perspectives
Terkawi, M. A., Matsumae, G., Shimizu, T., Takahashi, D., Kadoya, K., & Iwasaki, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031786 · Cited by 174
Osteoblasts Directly Control Lineage Commitment of Mesenchymal Progenitor Cells through Wnt Signaling
Zhou, H., Mak, W., Zheng, Y., Dunstan, C. R., & Seibel, M. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702687200 · Cited by 160
Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders
Vervloet, M. G., Massy, Z. A., Brandenburg, V. M., Mazzaferro, S., Cozzolino, M. G., Ureña, P., Bover, J., & Goldsmith, D. J. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70059-2 · Cited by 159
Wnt signaling and skeletal development
Liu, F., Kohlmeier, S. E., & Wang, C.-Y. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.11.011 · Cited by 162
Sclerostin Regulates Release of Bone Mineral by Osteocytes by Induction of Carbonic Anhydrase 2
Kogawa, M., Wijenayaka, A. R., Ormsby, R. T., Thomas, G. P., Anderson, P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2003 · Cited by 158
The Binding Between Sclerostin and LRP5 is Altered by DKK1 and by High-Bone Mass LRP5 Mutations
Balemans, W., Piters, E., Cleiren, E., Ai, M., Wesenbeeck, L. V., Warman, M. L., & Hul, W. V. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9130-9 · Cited by 148
Myeloma bone disease: from biology findings to treatment approaches
Terpos, E., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2019) · Blood · doi:10.1182/blood-2018-11-852459 · Cited by 151
Cortical-Bone Fragility — Insights from sFRP4 Deficiency in Pyle’s Disease
Simsek Kiper, P. O., Saito, H., Gori, F., Unger, S., Hesse, E., Yamana, K., Kiviranta, R., Solban, N., Liu, J., Brommage, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509342 · Cited by 151
Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling
Fulzele, K. S., Krause, D. S., Panaroni, C., Saini, V., Barry, K. J., Liu, X., Lotinun, S., Baron, R., Bonewald, L. F., Feng, J. Q., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437160 · Cited by 152
Sclerostin and DKK1: new players in renal bone and vascular disease
Evenepoel, P., D’Haese, P. C., & Brandenburg, V. M. (2015) · Kidney International · doi:10.1038/ki.2015.156 · Cited by 150
Cellular communications in bone homeostasis and repair
Nakahama, K. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0479-3 · Cited by 151
Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis
Carbonare, L. D., Valenti, M. T., Zanatta, M., Donatelli, L., & Cascio, V. L. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24884 · Cited by 145
Current advances in regulation of bone homeostasis
Al‐Bari, M. A. A., & Mamun, A. A. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00058 · Cited by 150
Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study
Garnero, P., Sornay‐Rendu, E., Munoz, F., Borel, O., & Chapurlat, R. D. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1978-x · Cited by 144
Regulation of Wnt/β-catenin signaling within and from osteocytes
Burgers, T., & Williams, B. O. (2013) · Bone · doi:10.1016/j.bone.2013.02.022 · Cited by 150
Osteoimmunology The i Nexus i between bone and immune system
Srivastava, R. K. (2017) · Frontiers in bioscience · doi:10.2741/4600 · Cited by 152
Sclerostin in Mineralized Matrices and van Buchem Disease
van Bezooijen, R. L., Bronckers, A. L. J. J., Gortzak, R. A. T., Hogendoorn, P. C. W., van der Wee-Pals, L. J. A., Balemans, W., Oostenbroek, H. J., Hul, W. V., Hamersma, H. A., Dikkers, F. G., et al. (2009) · Journal of Dental Research · doi:10.1177/0022034509338340 · Cited by 138
Self-citation
An Organoid for Woven Bone
Akiva, A., Melke, J., Ansari, S., Liv, N., van der Meijden, R., van Erp, M., Zhao, F., Stout, M., Nijhuis, W. H., de Heus, C., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202010524 · Cited by 138
The Wnt signaling pathway and bone metabolism
Johnson, M. L., & Kamel, M. A. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32816e06f9 · Cited by 140
Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes
Kim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137
Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?
Wilund, K. R. (2007) · Clinical Science · doi:10.1042/cs20060368 · Cited by 138
Effects of sclerostin antibodies in animal models of osteoporosis
Ominsky, M. S., Boyce, R. W., Li, X., & Ke, H. Z. (2016) · Bone · doi:10.1016/j.bone.2016.10.019 · Cited by 140
Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels
Morales, S., García-Fontana, B., García‐Martin, A., Rozas-Moreno, P., Garcia-Salcedo, J. A., Reyes‐García, R., & Muñoz‐Torres, M. (2013) · Diabetes Care · doi:10.2337/dc12-1691 · Cited by 135
Prostaglandin E2: From Clinical Applications to Its Potential Role in Bone- Muscle Crosstalk and Myogenic Differentiation
Mo, C., Romero‐Suarez, S., Bonewald, L. F., Johnson, M. L., & Brotto, M. (2012) · Recent Patents on Biotechnology · doi:10.2174/1872208311206030223 · Cited by 134
DNA methylation contributes to the regulation of sclerostin expression in human osteocytes
Delgado‐Calle, J., Sañudo, C., Bolado‐Carrancio, A., Fernández, A. F., Arozamena, J., Pascual-Carra, M. A., Rodríguez-Rey, J. C., Fraga, M. F., Bonewald, L. F., & Riancho, J. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1491 · Cited by 134
Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release
Qiao, H., Cui, Z., Yang, S., Ji, D., Wang, Y., Yang, Y., Han, X., Fan, Q., Qin, A., Wang, T., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b03197 · Cited by 133
A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice
Maupin, K. A., Droscha, C. J., & Williams, B. O. (2013) · Bone Research · doi:10.4248/br201301004 · Cited by 133
Modeling the Impact of Microgravity at the Cellular Level: Implications for Human Disease
Bradbury, P., Wu, H., Choi, J. U. A., Rowan, A. E., Zhang, H., Poole, K., Lauko, J., & Chou, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00096 · Cited by 141
Self-citation
Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice
Murali, S. K., Andrukhova, O., Clinkenbeard, E. L., White, K. E., & Erben, R. G. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002427 · Cited by 131
Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta
Sinder, B. P., Eddy, M. M., Ominsky, M. S., Caird, M. S., Marini, J. C., & Kozloff, K. M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1717 · Cited by 133
The Role of Macrophage in the Pathogenesis of Osteoporosis
Yang, D., & Yang, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092093 · Cited by 144
Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin
Stegen, S., Stockmans, I., Moermans, K., Thienpont, B., Maxwell, P. H., Carmeliet, P., & Carmeliet, G. (2018) · Nature Communications · doi:10.1038/s41467-018-04679-7 · Cited by 126
Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Osteocytes and WNT: the Mechanical Control of Bone Formation
Galli, C., Passeri, G., & Macaluso, G. M. (2010) · Journal of Dental Research · doi:10.1177/0022034510363963 · Cited by 136
Klotho expression in osteocytes regulates bone metabolism and controls bone formation
Komaba, H., Kaludjerovic, J., Hu, D. Z., Nagano, K., Amano, K., Ide, N., Sato, T., Densmore, M., Hanai, J.-I., Olauson, H., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.014 · Cited by 128
Wnt signaling and the regulation of bone mass
Baron, R., & Rawadi, G. (2007) · Current Osteoporosis Reports · doi:10.1007/s11914-007-0006-0 · Cited by 127
Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth
Delgado‐Calle, J., Anderson, J. L., Cregor, M. D., Condon, K. W., Kuhstoss, S., Plotkin, L. I., Bellido, T., & Roodman, G. D. (2017) · Leukemia · doi:10.1038/leu.2017.152 · Cited by 129
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide
Pοlyzos, S. A., Anastasilakis, A. D., Bratengeier, C., Woloszczuk, W., Παπαθεοδώρου, Α., & Terpos, E. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1525-6 · Cited by 126
Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications
Shim, J., Stavre, Z., & Gravallese, E. M. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0373-1 · Cited by 130
SaOS2 Osteosarcoma Cells as an In Vitro Model for Studying the Transition of Human Osteoblasts to Osteocytes
Prideaux, M., Wijenayaka, A. R., Kumarasinghe, D. D., Ormsby, R. T., Evdokiou, A., Findlay, D. M., & Atkins, G. J. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9879-y · Cited by 125
Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by γ-carboxylation-dependent and -independent mechanisms
Atkins, G. J., Welldon, K. J., Wijenayaka, A. R., Bonewald, L. F., & Findlay, D. M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00216.2009 · Cited by 132
Wnt signaling: A win for bone
Piters, E., Boudin, E., & Hul, W. V. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.006 · Cited by 126
Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice
Xiao, Z., Dallas, M., Qiu, N., Nicolella, D. P., Cao, L., Johnson, M. L., Bonewald, L. F., & Quarles, L. D. (2011) · The FASEB Journal · doi:10.1096/fj.10-180299 · Cited by 126
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 121
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels
Chang, M.-K., Krämer, I., Huber, T., Kinzel, B., Guth, S., Leupin, O., & Kneissel, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413828111 · Cited by 124
Serum Sclerostin and Risk of Hip Fracture in Older Caucasian Women
Arasu, A., Cawthon, P. M., Lui, L., Do, T. P., Arora, P. S., Cauley, J. A., Ensrud, K. E., & Cummings, S. R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3419 · Cited by 119
Does osteocytic SOST suppression mediate PTH bone anabolism?
Krämer, I., Keller, H., Leupin, O., & Kneissel, M. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.12.002 · Cited by 121
Sclerostin: A gem from the genome leads to bone-building antibodies
Pászty, C., Turner, C. H., & Robinson, M. K. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.161 · Cited by 120
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus
Hamann, C., Rauner, M., Höhna, Y., Bernhardt, R., Mettelsiefen, J., Goettsch, C., Günther, K., Stolina, M., Han, C.-Y. E., Asuncion, F., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1803 · Cited by 120
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone
Silvestrini, G., Ballanti, P., Leopizzi, M., Sebastiani, M., Berni, S., Vito, M. D., & BONUCCI, E. (2007) · Journal of Molecular Histology · doi:10.1007/s10735-007-9096-3 · Cited by 118
Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes
Gooi, J. H., Pompolo, S., Karsdal, M. A., Kulkarni, N. H., Kalajzic, I., McAhren, S. H. M., Han, B., Onyia, J. E., Ho, P. W. M., Gillespie, M. T., et al. (2010) · Bone · doi:10.1016/j.bone.2010.02.018 · Cited by 117
Osteocyte differentiation is regulated by extracellular matrix stiffness and intercellular separation
Mullen, C. A., Haugh, M. G., Schaffler, M. B., Majeska, R. J., & McNamara, L. M. (2013) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2013.06.013 · Cited by 117
Endoplasmic reticulum mediates mitochondrial transfer within the osteocyte dendritic network
Gao, J., Qin, A., Liu, D., Ruan, R., Wang, Q., Yuan, J., Cheng, T. S., Filipovska, A., Papadimitriou, J. M., Dai, K., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw7215 · Cited by 121
Roles of Wnt signals in bone resorption during physiological and pathological states
Maeda, K., Takahashi, N., & Kobayashi, Y. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0974-0 · Cited by 118
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
Estell, E. G., & Rosen, C. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00426-5 · Cited by 115
Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms
Chandra, A., Lin, T., Young, T. J., Tong, W., Ma, X., Tseng, W., Krämer, I., Kneissel, M., Levine, M. A., Zhang, Y., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2996 · Cited by 110
Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
Spaan, I., Raymakers, R. A. P., van de Stolpe, A., & Peperzak, V. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0615-3 · Cited by 114
The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities
Yu, M. S., Qin, K. H., Fan, J., Zhao, G., Zhao, P., Zeng, W., Chen, C., Wang, A., Wang, Y., Zhong, J., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.04.042 · Cited by 125
Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength
Yao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 116
Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
Viaene, L., Behets, G. J. S., Claes, K., Meijers, B. K. I., Blocki, F. A., Brandenburg, V. M., Evenepoel, P., & D’Haese, P. C. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft039 · Cited by 114
Targeting WNT signaling in the treatment of osteoporosis
Baron, R., & Gori, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.011 · Cited by 101
Cell Culture Systems for Studies of Bone and Tooth Mineralization
Boskey, A. L., & Roy, R. (2008) · Chemical Reviews · doi:10.1021/cr0782473 · Cited by 114
Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats
Taylor, S., Ominsky, M. S., Hu, R., Pacheco, E., He, Y. D., Brown, D. L., Aguirre, J. I., Wronski, T. J., Buntich, S., Afshari, C. A., et al. (2016) · Bone · doi:10.1016/j.bone.2015.12.013 · Cited by 106
Functions of the osteocyte network in the regulation of bone mass
Komori, T. (2013) · Cell and Tissue Research · doi:10.1007/s00441-012-1546-x · Cited by 113
Fate of growth plate hypertrophic chondrocytes: Death or lineage extension?
Tsang, K. Y., Chan, D. T.-M., & Cheah, K. S. E. (2015) · Development Growth & Differentiation · doi:10.1111/dgd.12203 · Cited by 110
Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
Wang, J. S., Mazur, C. M., & Wein, M. N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.584147 · Cited by 113
The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles.
Atkins, G., Welldon, K. J., Holding, C., Haynes, D., Howie, D., & Findlay, D. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.035 · Cited by 110
Mechanical Load Increases in Bone Formation via a Sclerostin-Independent Pathway
Morse, A., McDonald, M. M., Kelly, N. H., Melville, K. M., Schindeler, A., Krämer, I., Kneissel, M., van der Meulen, M. C. H., & Little, D. G. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2278 · Cited by 109
Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence
Giannoudis, P. V., Kanakaris, N. K., & Einhorn, T. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0441-x · Cited by 108
The effects of tumour necrosis factor‐α on bone cells involved in periodontal alveolar bone loss; osteoclasts, osteoblasts and osteocytes
Algate, K., Haynes, D. R., Bartold, P. M., Crotti, T. N., & Cantley, M. D. (2015) · Journal of Periodontal Research · doi:10.1111/jre.12339 · Cited by 108
Crosstalk Between MLO‐Y4 Osteocytes and C2C12 Muscle Cells Is Mediated by the Wnt/β‐Catenin Pathway
Huang, J. M., Romero‐Suarez, S., Lara, N., Mo, C., Kaja, S., Brotto, L. S., Dallas, S. L., Johnson, M. L., Jähn, K., Bonewald, L. F., et al. (2017) · JBMR Plus · doi:10.1002/jbm4.10015 · Cited by 107
Connexin 43 deficiency attenuates loss of trabecular bone and prevents suppression of cortical bone formation during unloading
Lloyd, S. A., Lewis, G. S., Zhang, Y., Paul, E. M., & Donahue, H. J. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1687 · Cited by 108
Osteocyte Network; a Negative Regulatory System for Bone Mass Augmented by the Induction of Rankl in Osteoblasts and Sost in Osteocytes at Unloading
Moriishi, T., Fukuyama, R., Ito, M., Miyazaki, T., Maeno, T., Kawai, Y., Komori, H., & Komori, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040143 · Cited by 105
Novel actions of sclerostin on bone
Holdsworth, G., Roberts, S. J., & Ke, H. Z. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0176 · Cited by 109
Molecular analyses of dinosaur osteocytes support the presence of endogenous molecules
Schweitzer, M. H., Zheng, W., Cleland, T. P., & Bern, M. W. (2012) · Bone · doi:10.1016/j.bone.2012.10.010 · Cited by 104
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys
Ominsky, M. S., Boyd, S. K., Varela, A., Jolette, J., Felx, M., Doyle, N. E., Mellal, N., Smith, S. Y., Locher, K., Buntich, S., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3036 · Cited by 104
Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass
Keaveny, T. M., Crittenden, D. B., Bolognese, M. A., Genant, H. K., Engelke, K., Oliveri, B., Brown, J. P., Langdahl, B. L., Yan, C., Grauer, A., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3176 · Cited by 104
Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
Gatti, D., Viapiana, O., Fracassi, E., Idolazzi, L., Dartizio, C., Povino, M. R., Adami, S., & Rossini, M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1681 · Cited by 102
Update in Osteoporosis and Metabolic Bone Disorders
Shoback, D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0042 · Cited by 100
Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin
Wang, J. S., Kamath, T., Mazur, C. M., Mirzamohammadi, F., Rotter, D., Hojo, H., Castro, C. D., Tokavanich, N., Patel, R., Govea, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26571-7 · Cited by 105
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease
Eda, H., Santo, L., Wein, M. N., Hu, D. Z., Cirstea, D. D., Nemani, N., Tai, Y., Raines, S. E., Kuhstoss, S. A., Munshi, N. C., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2789 · Cited by 100
Influences of the IL-6 cytokine family on bone structure and function
Sims, N. A. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155655 · Cited by 103
The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes
Napoli, N., Strollo, R., Paladini, A., Briganti, S., Pozzilli, P., & Epstein, S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/690783 · Cited by 105
Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system
Niedźwiedzki, T., & Filipowska, J. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0067 · Cited by 105
Sclerostin deficiency in humans
van Lierop, A. H., Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Bone · doi:10.1016/j.bone.2016.10.010 · Cited by 99
Self-citation
Profile of romosozumab and its potential in the management of osteoporosis
Lim, S. Y., & Bolster, M. B. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s127568 · Cited by 106
Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women
Sheng, Z., Tong, D., Ou, Y., Zhang, H., Zhang, Z., Li, S., Zhou, J., Zhang, J., & Liao, E. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04315.x · Cited by 99
Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots
Fulzele, K. S., Lai, F., Dedic, C., Saini, V., Uda, Y., Shi, C., Tuck, P., Aronson, J., Liu, X., Spatz, J., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3001 · Cited by 102
Phenotypic Characterization of Osteoarthritic Osteocytes from the Sclerotic Zones: A Possible Pathological Role in Subchondral Bone Sclerosis
Jaiprakash, A. T., Prasadam, I., Feng, J. Q., Liu, Y., Crawford, R., & Xiao, Y. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4221 · Cited by 98
Novel LRP5 Missense Mutation in a Patient With a High Bone Mass Phenotype Results in Decreased DKK1-Mediated Inhibition of Wnt Signaling*
Balemans, W., Devogelaer, J., Cleiren, E., Piters, E., Caussin, E., & Hul, W. V. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070211 · Cited by 97
Topical administration of simvastatin recovers alveolar bone loss in rats
Seto, H., Ohba, H., Tokunaga, K., Hama, H., Horibe, M., & Nagata, T. (2007) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2007.01024.x · Cited by 96
Emerging Regenerative Approaches for Periodontal Reconstruction: A Systematic Review From the AAP Regeneration Workshop
Zhao, L., Rios, H. F., & Cochran, D. L. (2015) · Journal of Periodontology · doi:10.1902/jop.2015.130689 · Cited by 96
Role of the Interaction of Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors 1 and 2 in Bone-Related Cells
Kitaura, H., Marahleh, A., Ohori, F., Noguchi, T., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., Kanou, K., & Mizoguchi, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031481 · Cited by 106
SP7 Inhibits Osteoblast Differentiation at a Late Stage in Mice
Yoshida, C. A., Komori, H., Maruyama, Z., Miyazaki, T., Kawasaki, K., Furuichi, T., Fukuyama, R., Mori, M., Yamana, K., Nakamura, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032364 · Cited by 94
Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation
Rauner, M., Sipos, W., & Pietschmann, P. (2008) · AGE · doi:10.1007/s11357-008-9069-9 · Cited by 93
Editorial: Sclerostin and Wnt Signaling—The Pathway to Bone Strength
Ott, S. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2370 · Cited by 93
Osteocytes and Estrogen Deficiency
McNamara, L. M. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00702-x · Cited by 93
Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer’s disease progression
Shi, T., Shen, S., Shi, Y., Wang, Q., Zhang, G., Lin, J., Chen, J., Bai, F., Zhang, L., Wang, Y., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00989-x · Cited by 87
Trabecular bone organoids: a micron-scale ‘humanised’ prototype designed to study the effects of microgravity and degeneration
Iordachescu, A., Hughes, E. A. B., Joseph, S., Hill, E. J., Grover, L. M., & Metcalfe, A. D. (2021) · npj Microgravity · doi:10.1038/s41526-021-00146-8 · Cited by 89
Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats
Li, X., Ominsky, M. S., Warmington, K. S., Niu, Q., Asuncion, F., Barrero, M., Dwyer, D., Grisanti, M. S., Stolina, M., Kostenuik, P. J., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0252 · Cited by 87

Authors: Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J.
Affiliations: University of Cambridge (GB)
Department of Endocrinology and Metabolic Diseases Leiden University Medical Centre Leiden Netherlands
South Africa
Leiden University (NL)
ORCID: Poole, Kenneth E. S.
Loveridge, Nigel
Hamersma, Herman
Papapoulos, Socrates E.
Löwik, Clemens W.
Reeve, Jonathan
Venue: The FASEB Journal
Publisher: Wiley
Published: 2005-08-25
Volume: 19
Issue: 13
Pages: 1842-1844
ISSN: 0892-6638 (ISSN-L)
1530-6860
DOI: 10.1096/fj.05-4221fje
OpenAlex: W1970864109
Cited by: 965
References: 34
Citations by year: 2026: 21 · 2025: 28 · 2024: 32 · 2023: 39 · 2022: 38 · 2021: 45 · 2020: 74 · 2019: 63 · 2018: 55 · 2017: 53 · 2016: 66 · 2015: 67 · 2014: 55 · 2013: 62 · 2012: 63
FWCI: 10.29
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: The FASEB Journal (publishedVersion)
PubMed (publishedVersion)
Funders: Medical Research Council
National Osteoporosis Society
European Commission (LSHM‐CT‐2003‐503020)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: sclerostin, osteocytes, bone formation inhibition, sclerosteosis, osteoblasts, bone mineralization, bone lining cells, bone turnover
MeSH terms: Aged, Alkaline Phosphatase, Antibodies, Monoclonal, Biopsy, Bone and Bones, Bone Development, Bone Diseases, Developmental, Bone Resorption, Cell Differentiation, Coloring Agents, Female, Genetic Markers, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Male, Microscopy, Fluorescence, Middle Aged, Models, Biological, Osteoblasts, Osteocytes, Osteogenesis, RNA, Messenger, Time Factors, Tolonium Chloride, Signal Transduction, Bone Remodeling, Bone Morphogenetic Proteins, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks